Global Patient-derived Xenograft (PDX) Models Market Growth (Status and Outlook) 2023-2029

Global Patient-derived Xenograft (PDX) Models Market Growth (Status and Outlook) 2023-2029

LPI (LP Information)' newest research report, the “Patient-derived Xenograft (PDX) Models Industry Forecast” looks at past sales and reviews total world Patient-derived Xenograft (PDX) Models sales in 2022, providing a comprehensive analysis by region and market sector of projected Patient-derived Xenograft (PDX) Models sales for 2023 through 2029. With Patient-derived Xenograft (PDX) Models sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Patient-derived Xenograft (PDX) Models industry.

This Insight Report provides a comprehensive analysis of the global Patient-derived Xenograft (PDX) Models landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Patient-derived Xenograft (PDX) Models portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Patient-derived Xenograft (PDX) Models market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Patient-derived Xenograft (PDX) Models and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Patient-derived Xenograft (PDX) Models.

The global Patient-derived Xenograft (PDX) Models market size is projected to grow from US$ 324.4 million in 2022 to US$ 587.7 million in 2029; it is expected to grow at a CAGR of 8.9% from 2023 to 2029.

Global top 5 manufacturers of patient-derived xenograft (PDX) models occupied for a share nearly 45 percent, key players are Crown Bioscience, Champions Oncology, Wuxi Apptec, EPO Berlin-Buch, and Oncodesign, etc. Geographically speaking, Asia Pacific holds the most of global market share, about 35%. North America holds about 30% of share, while Europe followed by nearly 20%. In terms of type, mouse model accounted for nearly 75%, and rat model accounted for a share of 25%,The application of patient-derived xenograft (PDX) models includes preclinical drug development and biomarker analysis. Preclinical drug development shares over 75%, while biomarker analysis shares about 20%.

This report presents a comprehensive overview, market shares, and growth opportunities of Patient-derived Xenograft (PDX) Models market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Mouse Model
Rat Model

Segmentation by application
Preclinical Drug development
Biomarker Analysis

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Crown Bioscience
Champions Oncology
Wuxi Apptec
The Jackson Laboratory
EPO Berlin-Buch
Oncodesign
Xentech
Envigo
Charles River Laboratories
Pharmatest Services
Urosphere
MEDICILON
Horizon Discovery
Shanghai Model Organisms Center
GemPharmatech
LIDE Biotech

Please note: The report will take approximately 2 business days to prepare and deliver.